- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00978367
Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)
A Double Blind, Placebo (Vehicle) and Standard Care Controlled, Randomised Study to Investigate the Clinical Safety and Toleration (Including Systemic Pharmacokinetics), Wound Healing and Anti-scarring Potential of Two Applications of Intradermal RN1001 in Healthy Male Subjects.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects were randomised into two cohorts, to receive either 5 ng avotermin doses or 50 ng doses, with a minimum of 21 subjects per cohort. Within each cohort subjects were randomised into one of three dosing groups (7 subjects per group).
Subjects were to receive four 3 mm punch biopsies, two on the upper-inner aspect of each arm. One treatment was randomly allocated to one biopsy on one arm, with the opposite biopsy on the other arm set to receive the same treatment. The other treatment was administered to the other two biopsies (one on each arm. This allowed for control of possible positional effects on healing.
Three subjects per group received intradermal avotermin to one of the biopsies on each arm and intradermal placebo to the other biopsies. A different three subjects received intradermal avotermin to one of the biopsies on each arm and standard care only to the other biopsies. The final subject per group received intradermal placebo to one of the biopsies on each arm and standard care only to the other biopsy.
On day 0 biopsy sites were marked on both arms and following local anaesthesia avotermin, placebo or nothing was injected intradermally into the allocated sites. Subjects in dosing frequency group 1 (DFG 1) were dosed only once (day 0), subjects in DFG 2 were dosed three times (day 0, 1 and 2) and subjects in DFG 3 were dosed five times (day 0, 1, 2, 3 and 4).
On Day 5, all subjects had their punch biopsy wounds on one arm only re-dosed as per Day 0 and then excised with a 5 mm surgical ellipse. Subjects in DFG2 and DFG3 received further re-dosing on their excised punch biopsies as before, i.e. three doses for DFG2 and five doses for DFG3.
Subjects returned for a first follow-up at day 14 and then at months 2, 4 and 6 to examine for anti-scarring effects. At month 6 all scars were excised for histological examination.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom, M13 9XX
- Renovo Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, non-Caribbean, male subjects aged 18-45 years inclusive
- Weight between 60-150 kg and a BMI within the permitted range for their height using Quetelet's index (15-45 kg/m(squared)) (weight (kg)/height (squared)(m))
- Subjects who have a previous history of surgery or minor injury and who have not developed any evidence of hypertrophic or keloid scar formation
Exclusion Criteria:
- Subjects who have a history or evidence of hypertrophic or keloid scarring
- Subjects with tattoos or previous scars in the area to be biopsied
- Subjects who have evidence of any past or present clinically significant disease, particularly coagulation disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo (vehicle)
|
Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
|
Experimental: Drug, intradermal avotermin (Juvista)
|
5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
Other Names:
5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
Other Names:
5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the dosing frequency of various concentrations of intradermal avotermin (Juvista) for the improvement of early wound healing and re-epithelialisation, as determined by measuring total wound diameter
Time Frame: Day 5 post surgery
|
Day 5 post surgery
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety and toleration of various concentrations of avotermin (Juvista) applied by intradermal injection at various timepoints
Time Frame: Days 0-14 post-wounding
|
Days 0-14 post-wounding
|
To determine the systemic exposure of various concentrations of avotermin (Juvista) applied by intradermal injection at various timepoints
Time Frame: Days 0-14 post-wounding
|
Days 0-14 post-wounding
|
To determine the gross and histological endpoints (re-epithelialisation and wound healing) of various concentrations of avotermin (Juvista) applied by intradermal injection at various dosing frequencies
Time Frame: 0-6 months post-wounding
|
0-6 months post-wounding
|
To determine the anti-scarring potential of two doses of avotermin (Juvista) when applied by intradermal injection at various dosing frequencies
Time Frame: Day 5 and 6 months post-wounding
|
Day 5 and 6 months post-wounding
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael J Davies, Renovo
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RN1001-319-1003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cicatrix
-
Samsung Medical CenterSeoul National University Hospital; Kyunghee University Medical Center; InovailUnknownHypertrophic CicatrixKorea, Republic of
-
Olix Pharmaceuticals, Inc.CompletedCicatrix, HypertrophicUnited Kingdom
-
HugelCompletedHypertrophic ScarKorea, Republic of
-
SolitonUnited States Naval Medical Center, San DiegoNot yet recruitingScars, Hypertrophic
-
Seton Healthcare FamilyCompleted
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedCicatrix, HypertrophicSpain
-
Nova Scotia Health AuthorityRecruiting
-
Henry Ford Health SystemActive, not recruitingScar | Hypertrophic ScarUnited States
-
Massachusetts General HospitalWithdrawnHypertrophic ScarsUnited States
-
University of California, Los AngelesWithdrawnCosmetics, Suture, CicatrixUnited States
Clinical Trials on Avotermin
-
RenovoUnknown
-
RenovoICON Clinical ResearchCompletedCicatrix | Varicose VeinsBelgium, United Kingdom, Latvia, Lithuania
-
RenovoCompleted
-
RenovoCompletedCicatrix | MammaplastyUnited Kingdom
-
RenovoTerminated
-
RenovoUnknownCicatrix | NevusUnited Kingdom
-
RenovoCompletedScar ImprovementUnited Kingdom
-
RenovoCompleted
-
RenovoCompleted
-
RenovoCompleted